Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
Philipp Fronik, Michael Gutmann, Petra Vician, et al.
Communications Chemistry (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

A chemical perspective on the clinical use of platinum-based anticancer drugs
Shoohb Alassadi, Michelle J. Pisani, Nial J. Wheate
Dalton Transactions (2022) Vol. 51, Iss. 29, pp. 10835-10846
Closed Access | Times Cited: 75
Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments
Tao Sun, Chen Jiang
Advanced Drug Delivery Reviews (2023) Vol. 196, pp. 114773-114773
Closed Access | Times Cited: 73
Research Progress of Disulfide Bond Based Tumor Microenvironment Targeted Drug Delivery System
Weiran Ma, Xiaoying Wang, Dongqi Zhang, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 7547-7566
Open Access | Times Cited: 18
Oxaliplatin and its derivatives – An overview
Paul O'Dowd, Darragh F. Sutcliffe, Darren M. Griffith
Coordination Chemistry Reviews (2023) Vol. 497, pp. 215439-215439
Open Access | Times Cited: 33
Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance
Meng Wang, Guimei Li, Guiyang Jiang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6218-6237
Closed Access | Times Cited: 8
Novel Indole–Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction
Zhikun Liu, Meng Wang, Ri-Zhen Huang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4868-4887
Closed Access | Times Cited: 22
Platinum(IV) and platinum(II) anticancer complexes with biologically active releasable ligands
Pavel Štarha, Radka Křikavová
Coordination Chemistry Reviews (2023) Vol. 501, pp. 215578-215578
Closed Access | Times Cited: 22
CJ2: A Novel Potent Platinum(IV) Prodrug Enhances Chemo-Immunotherapy by Facilitating PD-L1 Degradation in the Cytoplasm and Cytomembrane
Renming Fan, Aohua Deng, Bing Qi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 1, pp. 875-889
Closed Access | Times Cited: 21
Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
Alexander Kastner, Theresa Mendrina, Florian Bachmann, et al.
Inorganic Chemistry Frontiers (2023) Vol. 10, Iss. 14, pp. 4126-4138
Open Access | Times Cited: 21
The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives
Giulia Coffetti, Martina Moraschi, Giorgio Facchetti, et al.
Molecules (2023) Vol. 28, Iss. 8, pp. 3407-3407
Open Access | Times Cited: 18
Pt(iv) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?
Alvaro Lopez-Sanchez, Hélène Bertrand
Inorganic Chemistry Frontiers (2024) Vol. 11, Iss. 6, pp. 1639-1667
Closed Access | Times Cited: 7
Targeting Tumor Microenvironment by Metal Peroxide Nanoparticles in Cancer Therapy
Simon N. Mbugua
Bioinorganic Chemistry and Applications (2022) Vol. 2022, Iss. 1
Open Access | Times Cited: 25
Self-assembled hyaluronic acid nanomicelle for enhanced cascade cancer chemotherapy via self-sensitized ferroptosis
Jianbin Shi, Wenjing Ma, Jia Deng, et al.
Carbohydrate Polymers (2024) Vol. 343, pp. 122489-122489
Closed Access | Times Cited: 4
Exploring the Structure–Activity Relationships of Albumin-Targeted Picoplatin-Based Platinum(IV) Prodrugs
Martijn Dijkstra, Hemma Schueffl, Barbora Adamova, et al.
Inorganic Chemistry (2025)
Open Access
Multi-Pathway Study for Oxaliplatin Resistance Reduction
Tong Ye, Chen Wu, Jintong Na, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 172-172
Open Access
Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer
Kshitija Abhang, Sayali Dighe, Oly Katari, et al.
Drug Delivery and Translational Research (2025)
Closed Access
Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonists
Martijn Dijkstra, Michael Gutmann, Mathias Gradl, et al.
Inorganic Chemistry Frontiers (2025)
Open Access
The copper transporter CTR1 and cisplatin accumulation at the single-cell level by LA-ICP-TOFMS
Anna Schoeberl, Michael Gutmann, Sarah Theiner, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 17
The Power of Kinetic Inertness in Improving Platinum Anticancer Therapy by Circumventing Resistance and Ameliorating Nephrotoxicity
Tushar Ranjan Panda, M Manikandan, Shreyas P. Vaidya, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 38
Closed Access | Times Cited: 7
Remotely Controllable Supramolecular Nanomedicine for Drug‐Resistant Colorectal Cancer Therapy Caused by Fusobacterium nucleatum
Xiangjie Yan, Youtao Xin, Yunjian Yu, et al.
Small Methods (2023) Vol. 8, Iss. 3
Closed Access | Times Cited: 7
Stepwise optimization of tumor-targeted dual-action platinum(iv)-gemcitabine prodrugs
Alexander Kastner, Theresa Mendrina, Tomer Babu, et al.
Inorganic Chemistry Frontiers (2023) Vol. 11, Iss. 2, pp. 534-548
Open Access | Times Cited: 7
Cytotoxic Pt(ii) complexes containing alizarin: a selective carrier for DNA metalation
Rossella Caligiuri, Lara Massai, Andrea Geri, et al.
Dalton Transactions (2024) Vol. 53, Iss. 6, pp. 2602-2618
Open Access | Times Cited: 2
Discovery of the Next-Generation Platinum-Based Anticancer Agents for Combating Oxaliplatin-Induced Drug Resistance
Ziru Sun, Jianbin Han, Jun Xu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 12, pp. 10190-10210
Closed Access | Times Cited: 2
Chemotherapeutic Potential of Chlorambucil-Platinum(IV) Prodrugs against Cisplatin-Resistant Colorectal Cancer Cells
Maria George Elias, Angelico D. Aputen, Shadma Fatima, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8252-8252
Open Access | Times Cited: 2
AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer
Zhiwen Fu, Tingting Wu, Chen Gao, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 12, pp. 5305-5320
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top